A study of AZD3470, a PRMT5 inhibitor, in patients with MTAP deficient advanced/metastatic solid tumours - PRIMROSE

Study identifier:D9970C00001

ClinicalTrials.gov identifier:NCT06130553

EudraCT identifier:N/A

CTIS identifier:2023-506757-38

Recruiting

Official Title

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient

Medical condition

Advanced solid Tumours that are MTAP deficient

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD3470

Sex

All

Estimated Enrollment

210

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 19 Jan 2024
Estimated Primary Completion Date: 27 Feb 2026
Estimated Study Completion Date: 27 Feb 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria